https://www.selleckchem.com/products/gdc-0084.html
Glioblastoma patients administered standard therapies, comprising maximal surgical resection, radiation therapy with concomitant and adjuvant temozolomide, have a variable prognosis with a median overall survival of 15-16 months and a 2-year overall survival of 30%. The aim of this study was to develop a prognostic nomogram for overall survival for glioblastoma patients treated with standard therapy outside clinical trials. The study included 680 consecutive, non-selected glioblastoma patients administered standard therapy as primary t
Like
Comment
Share
